Protein tyrosine kinase modulators and methods of use

US9783524B2 · kind B2 · utility

Assignee

• Betta Pharmaceuticals Co., Ltd · CN

Inventors

• Shaojing Hu · Beijing, CN
• Xiangyong LIU · Beijing, CN
• Jinlong Bai · Beijing, CN
• Wei Long · Beijing, CN

Key dates

• Filing date: Jul 11, 2014
• Grant date: Oct 10, 2017
• Expiry date: Jul 11, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Heterocyclic pyrimidine compounds that modulate mutant-selective epidermal growth factor receptor (EGFR) and ALK kinase activity are disclosed. More specifically, the invention provides pyrimidines which inhibit, regulate and/or modulate kinase receptor, particularly in selectively modulation of various EGFR mutant activity and ALK kinase activity have been disclosed. Pharmaceutical compositions comprising the pyrimidine derivative, and methods of treatment for diseases associated with protein kinase enzymatic activity, particularly EGFR or ALK kinase activity including non-small cell lung cancer comprising administration of the pyrimidine derivative are disclosed.